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Abstract
Background: The progress of the prostate-specific antigen (PSA) level after radical
prostatectomy is observed for a patient in order to extract information about the
mode of tumor cell growth. Although PSA values are determined routinely to find
the doubling time of the prostate marker, to our knowledge, this analysis is the first
in the literature.
Results: The prostate tumor marker values were determined regularly after the
surgery and plotted on a logarithmic scale against time. An initial rapid-growth
mode changed to a slower power-law regime within two years of surgery. Our
analysis associates this observation with a transition in the growth mode from
unrestricted growth of dispersed cells to their clumping into macroscopic structures.
Conclusions: Such studies may help determine the appropriate time window for
postoperative therapies in order to increase the life expectancy of the patient.
Background
Cancer of the prostate gland is one of the most frequently diagnosed male illnesses and
may lead to death of the patient. The carcinoma is routinely detected by a straight-
forward blood test that measures a glycoprotein called prostate-specific antigen (PSA).
At an early stage of cancer growth with a localized tumor, radical removal of the pros-
tate gland has proved to be the optimum treatment. If the PSA value rises after radical
prostatectomy, different alternatives for treatment are currently under debate. The
doubling time (DT) of the PSA value is accepted as a strong prognostic factor for the
risk of cancer death. In a group of 379 patients, almost no prostate cancer deaths were
recorded within approximately 4 years of prostate removal for 3 < DT < 8.9 months,
while some patients with DT < 3 months died within 1.5 years [1]. It is therefore rea-
sonable to infer that findings during the last few years based on long-term statistics
suggest a longer life expectancy for patients with postoperative radiotherapy that fol-
lows (within 6 months of) radical prostate surgery [2]. Transdermal radiotherapy is
commonly applied after the PSA level reaches a threshold value. However, a wait-and-
watch method may cost valuable time and the relevant moment for action may be
missed regardless of how low the threshold value is set. Many authors have already
suggested [3-5] that the entire course of tumor growth offers important information
regarding the clinical strategies to be followed.
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reproduction in any medium, provided the original work is properly cited.The purpose of this work is threefold. (a) To indicate the possibility of detecting fast
(exponential) growth of the PSA score well before an arbitrary threshold value is
reached, thus gaining time for deciding the therapies to be followed. In principle, this
strategy is analogous to determining theD T .( b )T oa n a l y z eP S Ad a t ai naw a yt h a t
reveals a sharp crossover from exponential to power-law growth. (c) To propose a sim-
ple model to explain the crossover to slower (power-law) growth.
The second, slower growth regime, we argue, arises because of the coalescence or
“condensation” [6] of freely-dividing cancerous cells to form one or more compact
tumors, with growth essentially confined to the edges or the surface [4,5,7]. It has been
pointed out that at this stage (i) “sensitivity to anti-metabolic drugs decreases, ... (since
the fraction of) tumor cells that are in the cell division cycle decreases” [3] and (ii)
angiogenesis is expected to start [5].
Results
Case presentation
After a radical prostatovesiculectomy (pT2c N0 M0 G2, Gleason 3+4 = 7) applied to
one of us (ME), PSA values were determined with state-of-the-art precision using con-
stant laboratory conditions (Viollier, Brunngasse 6, CH-8401 Winterthur) at time inter-
vals of initially 6 months (see Table 1). The error in time measure was ± 0.5, while
each PSA value was determined with an uncertainty of ± 0.002 μg/l. In Figure 1 we
plot the values listed in the table as a function of time t in months after the surgery.
The graph has a characteristic “U” shape, i.e., a shallow increase during the first two
years and a steep rise in the last two.
In order to determine the kinetics of cell growth underlying the PSA progression,
we present the same PSA values as a function of time in Figure 2a, but plotted on a
semi-logarithmic scale. From the time of surgery until about 30 months thereafter
we observe a clear linear increase. Analytically, this corresponds to “exponential
growth”, with the functional form ~exp(pt), where p is a constant rate of cell divi-
sion. This can be determined at an early stage, before an arbitrary threshold value is
attained.
Table 1 Measured PSA scores
Date of the PSA test Time after the operation (months) PSA score (μg/l)
Aug. 2003 5 0.006
Feb. 2004 11 0.012
Aug. 2004 17 0.019
Feb. 2005 23 0.037
Aug. 2005 29 0.044
Feb. 2006 35 0.099
Aug. 2006 41 0.170
Nov. 2006 44 0.144
Feb. 2007 47 0.168
May 2007 50 0.294
Jul. 2007 52 0.262
Feb. 2008 59 0.295
Aug. 2008 65 0.485
The PSA values and the dates of measurement after the operation in March 2003 as well as the time elapsed thereafter.
Erbudak and Erzan Theoretical Biology and Medical Modelling 2010, 7:30
http://www.tbiomed.com/content/7/1/30
Page 2 of 7Later values are noisier and remain below the straight line, implying a different,
slower growth law. In Figure 2b we examine the departure from exponential behavior
by displaying the PSA values vs. time on a log-log plot. Here a straight line signifies a
power law (with the functional form ~t
u). There is sharp crossover from exponential
to power-law behavior at about two years after the surgery, rather than a gradual slow-
ing down. From this point on, up to the last measured value, the PSA values grow as a
power of the time elapsed after the crossover point.
Growth modes
We assume that the PSA value is linearly proportional to the number N of carcinoma
cells and that, initially, each cell freely divides at a constant rate p (probability per unit
time). For such unrestricted growth, the number of cells, N, increases by pN per unit
time on average, i.e.,
dd Nt p N /. = (1)
Figure 1 Linear plot of PSA score vs. time. PSA values in μg/l are displayed as a function of
measurement time in months after the surgery.
Figure 2 Logarithmic plot of PSA score vs. time. PSA values plotted on a logarithmic scale against (a)
linear time and (b) time on a logarithmic scale. Note that the straight line fit in panel (a) signals
exponential growth, while that in panel (b) indicates “power-law” growth (see text). The vertical size of the
first four points indicates the estimated error, while in the subsequent points the error bars are smaller
than the size of the plotted points.
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Nt N p t () 0 = exp( ), (2)
where N0 is the number at t = 0. The growth rate p is the only relevant parameter
that has to be experimentally determined.I nt h i st y p eo fg r o w t h ,t h eb i r t ho fan e w
cell has no effect on that of subsequent cells.
A st h en u m b e ro fm a l i g n a n tc e l l sg r o w sw i t h i nt h et i s s u e ,t h e r em u s tb eas p o n t a -
neous formation of macroscopic clusters of cells (i.e., tumors) that mop up almost all
the microscopic clusters, at a rather sharp transition point, the so-called percolation
threshold [8]. We identify this threshold with the crossover observed in Figure 2b.
Once clusters are formed, growth is confined to the surface of the tumor [5] and the
kinetic equations should only involve the number Ns of actively dividing cells in the
surface layer.
T h en u m b e ro fc e l l si nt h et u m o ri sr o u g h l yN ~ R
D where R is the average radius
and D is the dimension of the cluster. The number in the surface layer will grow as Ns
~ R
S,w i t hS being the surface dimension [9]. In the most general case where D ≤3,
Equation 1 is replaced by
dd Nt p k Rp k N
SS D /,
/ == 12 (3)
where k1 and k2 are constant geometrical factors, leading to
Ncc t
u =+ () . 12 (4)
Here uDDS c u N
u =− = /( ),
/
10
(1 ) ,w i t hN0 having the same meaning as in Equation
1, and c2 = pk2. Irrespective of the exact value of the exponent, for a sufficiently small
c1, Equation 3 predicts power-law growth. For spheroidal tumors [7] with growth con-
fined to the surface region, u = 3. The parameter u is related to the compactness or
looseness of the clumps of malignant cells and has to be determined experimentally.
Data analysis
Figure 2a confirms exponential growth of the initial PSA scores with a rate of p =
0.090 ± 0.004 per month. Thus, the DT is about 8 months [DT in months is given by
(ln 2)/p], or the PSA score increases by more than a factor of three within a year. In
current practice, each datum point at a particular time is used by the physician to
assess the patient’s health condition and to decide upon further action. Although the
absolute PSA values are much lower than the widely accepted threshold values for the
recurrence of prostate cancer, the growth rate is alarmingly fast. Yet after about three
years, the growth rate has slowed down and is seen to deviate from exponential beha-
vior. Nevertheless, any arbitrarily set threshold will eventually be attained.
T h el o g - l o gp l o to ft h eP S Av a l u e sv s .t i m ei nF i g u r e2 bs h o w sac r o s s o v e rf r o ma n
exponential to a power law. The value of the exponent is u = 2.57 ± 0.07, very close to
what would be predicted for percolation clu s t e r s[ 8 , 9 ]w i t hg r o w t hc o n f i n e dt oa n
outer shell.
T h ev a l u e sf o rt h ec o e f f i c i e n tp in the exponential form exp(pt) and the exponent u
in the form t
u are found from least squares fits to the linear parts of the plot in the
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precise numerical values of p or u, although with a linear fit to the straight lines in the
two plots these can be determined to an accuracy of two (one) significant digits (digit),
respectively, with Pearson’s correlation coefficients of r
2 = 0.98 and 0.96. The point is
that there is an unambiguous crossover, from a characteristically exponential to a char-
acteristically power-law behavior.
Discussion
The “Gompertzian” [10] growth curve widely accepted as a “universal law”
[3-7,11-14] for the growth of diverse populations including tumors and cell cultures
[13] exhibits initial exponential growth, gradually slowing down and finally saturating
(in vitro) to a constant value. We find that the data reported in Table 1 are also
fitted reasonably well by a Gompertzian (see Figure three of Ref [14]). It would be
worthwhile to re-plot the data traditionally analyzed within this gradualist picture on
a log-log scale, and see whether the same sharp crossover behavior is actually hiding
there as well.
Once the switch to power-law growth occurs, signalling discrete, compact tumors,
w ec a ne s t i m a t et h e i rs i z ea s s u m i n gt h a tt h eP S Av a l u ei sl i n e a r l yp r o p o r t i o n a lt ot h e
total number of malignant cells and knowin gt h eP S Av a l u ea n dt u m o rs i z eo b t a i n e d
from magnetic-resonance imaging (MRI) at the time of the operation.
In the particular case under study, the gland, prior to its removal, had a diameter of
less than 40 mm (Huber D: MRI Report. Zurich: Klinik Hirslanden; 2002) and the PSA
value was 8.5 μg/l. The prostate was about 50% cancerous according to the post-opera-
tive biopsy, so we deduce that a PSA level of 0.485 μg/l, measured at t =6 5 ,w o u l d
correspond to a tumor (consisting only of cancerous cells) approximately 5 mm in dia-
meter. If not one but two equally-sized compact clusters condense out of the scatter of
individual cells, our naive calculation gives a diameter of approximately 4 mm for each
of those tumors. Digital rectal examinations by three independent experts (Brodmann
S; Riesterer O; Vollenweider P; 2008) as well as the MRI analysis (Hilfiker P: Medical
Report. Zurich: MRI Bethanien; 2008) performed at t = 67 revealed two masses of
about 4 mm in agreement with our prediction. Subsequently, the subject received 70
Gy of radiation therapy in the anastomosing region during weekdays of t =6 8a n d6 9
in equal doses, with full bladder and an inflated (50 ml) rectal balloon. The volume
was reduced after 46 Gy in order to spare the vicinity. Since the radiation therapy, the
PSA values have remained around 0.16 μg/l.
Conclusions
We find that the PSA values of this patient after surgery follow an initial exponential
growth curve, with a sharp crossover to a slower power-law regime at around 20
months. We argue that this may be due to the clumping of individual cancerous cells
into macroscopic structures with distinct surfaces, to which subsequent growth is
confined.
In the present case, after the onset of the power-law growth regime, it was possible
to detect the clusters of cells, i.e., the tumors, via standard imaging techniques, and
verify that their sizes coincided with predictions from the model.
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our simple analysis, however, makes it highly worthwhile to monitor the PSA scores
closely during the so-called wait-and-watch period no matter how low their absolute
value is, as has been done in the present case, in order not to miss the optimum time
window for post-operative therapy to increase the life expectancy of the cancer patient.
The doubling time is a widely-used characteristic of cell growth and a constant value
testifies to exponential growth. The novel aspect of our analysis deals with the devia-
tion from exponential behavior, which transforms into a subsequent power-law regime.
Though mathematically convincing, this non-exponential late-stage growth behavior
observed for one particular patient may not represent a universal phenomenon. How-
ever, monitoring the growth of the PSA value as a function of time may provide the
opportunity for observing such a crossover, as for this patient. If such a crossover
indeed occurs, it may indicate, as explained above, the formation of macroscopic
masses within the tissue, and we suggest that this may be taken as a clue for deciding
upon post-operative treatment.
Consent
Written informed consent for publication was obtained from the patient, who is one of
the authors (ME), for publication of this case report and accompanying images. A copy
of the written consent is available for review by the Editor-in-Chief of this journal.
Acknowledgements
ME thanks Drs. M Dubs and P Vollenweider for fruitful discussions during the active surveillance throughout the years
before and after prostate surgery. AE would like to thank M Kardar for a helpful comment and also acknowledge
partial support by the Turkish Academy of Sciences.
Author details
1Laboratory for Solid State Physics, ETH Zurich, CH-8093 Zurich, Switzerland.
2Department of Physics, Faculty of Letters
and Sciences, Istanbul Technical University, Maslak, 34469 Istanbul, Turkey.
Authors’ contributions
The authors contributed equally to this work, and read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 11 May 2010 Accepted: 30 July 2010 Published: 30 July 2010
References
1. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW: Death in patients with
recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their
associated contributions to all-cause mortality. J Clin Oncol 2007, 25:1765-71.
2. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset J-F, van
Velthoven R, Maréchal J-M, Scalliet P, Haustermans K, Piérart M: Postoperative radiotherapy after radical
prostatectomy: a randomised controlled trial. Lancet 2005, 366:572-578.
3. Schabel FM Jr: The use of tumor growth kinetics in planning “curative” chemotherapy of advanced solid tumors.
Cancer Res 1969, 29:2384-2389.
4. Brú A, Albertos S, Subiza JL, Garcia-Asenjo JL, Brú I: The universal dynamics of tumor growth. Biophys J 2003,
85:2948-2961.
5. Kohandel M, Kardar M, Milosevic M, Sivaloganathan S: Dynamics of tumor growth and combination of anti-
angiogenic and cytotoxic therapies. Phys Med Biol 2007, 52:3665-3677.
6. Torkington P: Kinetics of deterrence of Gompertzian growth. Bull Math Biol 1983, 45:21-31.
7. Delsanto PP, Guiot C, Degiorgis PG, Condat CA, Mansury Y, Deisboek TS: Growth model for multicellular tumor
spheroids. App Phys Lett 2004, 85:4225-4227.
8. Stauffer D, Aharony A: Introduction to Percolation Theory London: Taylor and Francis 1992.
9. Mandelbrot BB: The Fractal Geometry of Nature New York: Macmillan 1983.
10. Gompertz B: On the nature of the function expressive of the law of human mortality, and on a new mode of
determining the value of life contingencies. Phil Trans R Soc 1825, 115:513-583.
11. DeWys WD: Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-
related systemic growth-related factors. Cancer Res 1972, 32:374-379.
Erbudak and Erzan Theoretical Biology and Medical Modelling 2010, 7:30
http://www.tbiomed.com/content/7/1/30
Page 6 of 712. Iwata K, Kawasaki K, Shigesada N: A dynamical model for the growth and size distribution of multiple metastatic
tumors. J Theor Biol 2000, 203:177-186.
13. Norton L, Simon R, Brereton HD, Bogden AE: Predicting the course of Gompertzian growth. Nature 1976, 264:542-545.
14. Guiot C, Degiorgis PG, Delsanto PP, Gabriele P, Deisboek TS: Does tumor growth follow a “universal law"? J Theor Biol
2005, 225:147-151.
doi:10.1186/1742-4682-7-30
Cite this article as: Erbudak and Erzan: Tracking tumor evolution via prostate-specific antigen: an individual post-
operative study. Theoretical Biology and Medical Modelling 2010 7:30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Erbudak and Erzan Theoretical Biology and Medical Modelling 2010, 7:30
http://www.tbiomed.com/content/7/1/30
Page 7 of 7